BioCentury
ARTICLE | Company News

Express Scripts adds Aimovig, Emgality to new value-based migraine program; excludes Ajovy

October 19, 2018 6:02 PM UTC

Express Scripts Holding Co. (NASDAQ:ESRX) will include two of three FDA approved migraine prevention drugs in its value-based program for migraine, which it unveiled Oct. 17. The PBM gave the nod to Aimovig erenumab-aooe from Amgen Inc. (NASDAQ:AMGN) and Novartis AG (NYSE:NVS; SIX:NOVN) and Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY), but excluded Ajovy fremanezumab-vfrm from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA). Express Scripts spokesperson Jennifer Luddy declined to disclose why the PBM excluded Ajovy.

Under the value-based program slated to begin April 1, Express Scripts will reach out to patients using acute migraine therapy frequently and their physicians to see if preventive therapy would be appropriate, Luddy said...